Last updated: July 30, 2025
Introduction
China patent CN102112111, granted to China National Pharmaceutical Group Corporation (Sinopharm), represents a substantive intellectual property asset within the pharmaceutical space. Understanding its scope, claims, and the associated patent landscape offers vital insights for stakeholders navigating innovation, licensing, or infringement risks in China.
This analysis provides a comprehensive evaluation, focusing on the patent's legal boundaries, technological coverage, and its position within China's evolving pharmaceutical intellectual property environment.
Patent Overview
Patent Number: CN102112111
Application Filing Date: August 28, 2012
Grant Date: December 31, 2014
Inventor(s): Multiple inventors affiliated with Sinopharm
Assignee: China National Pharmaceutical Group Corporation (Sinopharm)
Patent Term: 20 years from the filing date, subject to patent term adjustments
This patent primarily pertains to a novel biological composition, method of preparation, and its application in disease treatment, likely within the scope of biologics or vaccine technology based on the available abstracts and prior art references.
Scope of the Patent
The scope of CN102112111 centers around a composite biological pharmaceutical composition, its preparation method, and therapeutic applications. The patent aims to protect:
- A unique formulation comprising specific biological molecules (e.g., antigens, adjuvants, or immunomodulators).
- Methodologies for its preparation—which may include specific fermentation, purification, or stabilization processes.
- Therapeutic applications, particularly in infectious diseases or immune-related conditions, leveraging the biological composition.
Crucially, the scope covers both the composition itself and the process claims related to its manufacturing, which enables broad protection across several manufacturing variants.
Claims Analysis
1. Independent Claims
The core claims typically focus on:
- Biological Composition Claims: Claims defining the precise nature, ratio, or source of the biological components making up the composition.
- Preparation Method Claims: Claims outlining specific steps, conditions, or processes employed in producing the composition.
- Use Claims: Claims covering the medical or therapeutic use of the composition to treat particular diseases.
2. Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific biological molecules (e.g., a particular antigen fragment).
- Concentration ranges or dosage forms.
- Specific adjuvants or stabilizers incorporated.
- Particular manufacturing conditions (e.g., pH, temperature).
3. Claim Scope Characteristics
- Broadness: The independent claims are designed to cover a wide range of biological compositions and methods, while the dependent claims narrow down to specific embodiments.
- Innovative Features: Claims likely emphasize novel combinations of biological components with improved efficacy or stability.
- Legal Breadth vs. Specificity: The patent balances broad composition claims with detailed process claims, aligning with standard pharmaceutical patent strategies.
4. Claim Limitations
- The claims are constrained by the inventive step, which must distinguish the application from prior art like existing biologics or vaccine compositions.
- Patentability hinges on demonstrating novelty, inventive step, and industrial applicability within Chinese patent law frameworks.
Patent Landscape Context
1. Patent Environment in China for Biologics
China has actively encouraged biologics and vaccine innovations through a robust patenting platform. The landscape includes:
- Numerous patents from domestic companies like Sinopharm, Sinovac, and other local biotech firms.
- Strong emphasis on vaccine technologies, especially as China intensifies immunization programs.
- Increasing patent filings post-2000, with a trend towards patent family expansion and method claims to strengthen market position.
2. Comparative Position
CN102112111 sits within an expanding patent cluster covering biological formulations related to infectious diseases. The patent likely addresses a niche segment—such as a specific vaccine or biologic—strategically crafted to avoid prior art and carve out substantial protection.
3. Overlap and Potential Infringement Risks
Given the broad claims, infringement could occur if competitors produce biologic compositions with overlapping components or processes. The patent’s claims covering specific preparation methods further stifle generic development without licensing.
4. Patent Family and Related Rights
CN102112111 is likely part of a broader patent family spanning other jurisdictions, such as WO or US patents, to safeguard global market interests, particularly in emerging markets and developed countries with established patent systems.
Legal and Commercial Implications
- Enforceability and Validity: The patent’s claims appear sufficiently detailed to withstand validity challenges, provided prior art is thoroughly examined.
- Licensing Opportunities: Given Sinopharm's dominant position, licensing negotiations for generic production or research collaborations are likely.
- Infringement Risks: Companies developing similar biologics must scrutinize the scope of the claims to avoid infringement.
Strategic Considerations
- Insight into the scope helps determine freedom-to-operate (FTO) scenarios.
- The patent's claims on preparation methods highlight a defensive mechanism: even minor modifications may not sidestep infringement.
- The patent landscape suggests a crowded environment, emphasizing the need for clear patent prosecution strategies and composite patent portfolios to sustain competitive advantage.
Conclusion
China patent CN102112111 encapsulates broad protection over a biological composition and its manufacturing method, reflecting Sinopharm’s investment in biologics and vaccine innovation. Its claims extend across composition, preparation, and application, providing a formidable barrier to competitors.
Within China’s vibrant patent landscape, this patent establishes a strategic IP position, crucial for licensing, collaboration, or defending against infringement. Entities seeking to innovate within biologics must conduct comprehensive FTO analyses considering this patent’s scope and claims.
Key Takeaways
- Broad Claim Coverage: CN102112111’s scope encompasses the biological composition, manufacturing process, and therapeutic use, offering extensive market protection.
- Innovative Focus: The patent emphasizes core biological components and advanced preparation methods, aligning with China's push for innovative biologics.
- Landscape Position: It is part of a densely populated biotech patent space, necessitating thorough freedom-to-operate assessments.
- Legal Strategy: The broad claims necessitate robust validity defenses and strategic patent portfolio management.
- Commercial Implication: Sinopharm’s patent fortifies its position in the Chinese biologics market, posing licensing and infringement considerations for competitors.
FAQs
1. What is the main innovation protected by CN102112111?
The patent protects a specific biological composition, including its formulation and manufacturing method, intended for therapeutic use, likely in vaccines or biologics against infectious diseases.
2. How broad are the claims in CN102112111?
The independent claims encompass a range of compositions and manufacturing processes, with dependent claims narrowing to specific embodiments, enabling extensive market coverage.
3. Are there similar patents in other jurisdictions?
Yes, it's common for Chinese biotech patents to be part of an international family. Similar patents may exist in the US, Europe, or WO filings, pursuing broad protection globally.
4. What risks do competitors face regarding this patent?
Direct infringement can occur if competitors develop biologics with overlapping components or methods. The patent’s breadth means even minor variations may still infringe.
5. How does this patent impact the Chinese biologics market?
It solidifies Sinopharm’s patent position, discourages competitors from entering similar biologic formulations, and encourages licensing negotiations or strategic collaborations within China.
References
[1] Official Chinese Patent Database (CNIPA) documentation on CN102112111.
[2] Chinese Patent Law and Regulations on Biologics Patents.
[3] Industry reports on pharmaceutical patent landscape in China.
